Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder? (original) (raw)
Related papers
Management Strategies for Premenstrual Syndrome/Premenstrual Dysphoric Disorder
Annals of Pharmacotherapy, 2008
U p to 90% of women of childbearing age report experiencing premenstrual symptoms at some point in their lives. A smaller subset (up to 20%) report severe symptoms of premenstrual syndrome (PMS) that warrant treatment, and 3-8% are diagnosed as having a severe form known as premenstrual dysphoric disorder (PMDD). 1-3 This comprehensive review discusses the prevalence, etiology, symptomatology, and treatment of PMS/PMDD.
New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder
Archives of Women's Mental Health, 2002
Premenstrual dysphoric disorder was discussed by a panel of European researchers. The criteria for diagnosis of the condition, its categorisation as a mental disorder, and its differentiation from depression and premenstrual syndrome are all considered. Data on the treatment of premenstrual dysphoric disorder, using serotonin reuptake inhibitors and other therapies, are reviewed. An algorithm for the treatment of premenstrual dysphoric disorder is proposed.
Premenstrual syndrome and its psychiatric ramifications
Annals of Saudi medicine
Premenstrual syndrome and its psychiatric ramifications To the Editor: The article by Drs. Perveen Rasheed and Latifa Saad Al-Sowailem is interesting and the first of its kind that describes the prevalence and predictors of premenstrual syndrome in Saudi Arabia.1 However, we have reviewed the literature on premenstrual syndrome [PMS] and premenstrual dysphoric disorder [PMDD].2 Further, we have also reported five cases of PMS and its psychological connections to premenstrual dysphoric disorder.3 In a related development, Al-Habeeb also briefly reviewed the pertinent data and reported a case of premenstrual manic disorder, and based on four reported cases in the world literature, proposed tentative research diagnostic criteria.4 We observed that the two premenstrual syndromes with specific differentiating symptoms were etiologically attributed best to the dysregulation of central serotonergic and gabaergic systems and the noxious sex steroid hormonal milieu during normal cyclical ovulation. Further, the women with these syndromes, who need proper assessment, tests, and a correct diagnosis, respond effectively to selective serotonin-reuptake inhibitors, gonadotrophin-releasing hormone agonists, a novel contraceptive pill-Yasmin, cognitive-behavior therapy, lifestyle changes, and in addition, placebo. The oral contraceptive pill-Yasmin contains low-dose (30 microg) ethinylestradiol (EE) combined with a new progestogen, drospirenone (3 mg) (DRSP) and it offers better clinical efficacy for PMS/PMDD as a result of the unique pharmacological profile of this progestogen, which is a 17alpha-spirolactone derivative with antimineralocorticoid and antiandrogenic activity. Notably, DRSP resembles endogenous progesterone. Unlike other oral contraceptives, it has very minimal effects on skin, appetite, food craving, mood changes
Premenstrual dysphoric disorder: a review for the treating practitioner
Cleveland Clinic journal of medicine, 2004
Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS), is characterized by physical and behavioral symptoms that cause marked social impairment during the last half of the menstrual cycle. Symptoms are believed to result from the interaction of central neurotransmitters and normal menstrual hormonal changes. Treatment usually begins with lifestyle changes, over-the-counter medications, and if needed, selective serotonin reuptake inhibitors. Physicians should be aware of the risks of many of the alternative therapies commonly touted in the popular press.
The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD)
Psychoneuroendocrinology, 2003
Currently it is estimated that 3-8% of women of reproductive age meet strict criteria for premenstrual dysphoric disorder (PMDD). Assessment of published reports demonstrate that the prevalence of clinically relevant dysphoric premenstrual disorder is probably higher. 13-18% of women of reproductive age may have premenstrual dysphoric symptoms severe enough to induce impairment and distress, though the number of symptoms may not meet the arbitrary count of 5 symptoms on the PMDD list.
Depression and anxiety, 2017
Although traditionally dosed combined oral contraceptives (COCs) (21 days of active pills, 7 days of inactive pills) have not been demonstrated as superior to placebo for the treatment of premenstrual dysphoria (PMD), some randomized controlled trials (RCTs) indicate that oral contraceptives administered with a shortened or eliminated hormone-free interval are superior to placebo. However, results of such trials are mixed, and no existing studies have directly compared continuous and intermittent dosing schedules of the same oral contraceptive. The present study compared placebo, intermittent dosing of oral contraceptives, and continuous dosing of contraceptives for the treatment of PMD. Fifty-five women with prospectively confirmed PMD completed a three-arm, RCT in which they were randomized to 3 months of placebo (n = 22), intermittent drospirenone/ethinyl estradiol dosed on a 21-7 schedule (n = 17), or continuous drospirenone/estradiol (n = 16) following a baseline assessment mon...
Pharmacotherapy for premenstrual dysphoric disorder: A meta-analysis of phase 3 trials
Korean Journal of Obstetrics & Gynecology, 2012
Premenstrual dysphoric disorder (PMDD) is a common condition that temporarily, but repetitively affects patient's global function. Patients and physicians alike are often uncertain whether prescription medication for PMDD is suffi ciently effective. The primary objective of this analysis is signal detection in effi cacy of pharmacological treatments in PMDD. Secondary objective is to review which symptoms are likely to respond to which medications. The review included otherwise healthy women with clinician confi rmed diagnosis of PMDD who participated in phase 3 clinical trials for the treatment of PMDD. Twelve pair-wise comparisons of drug and placebo for 2,420 patients with PMDD were performed. Oral contraceptives and selective serotonin receptor inhibitor were effective in alleviating symptoms of PMDD compared to placebo. Both Intermittent and continuous administration were more effective than placebo. This meta-analysis provides a signal that pharmacological treatment of PMDD is effective.